Minerva Neurosciences (NERV) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed Nkarta (NKTX) over the past year, gaining 13.8% versus a gain of 6.2%. Over five years, NERV leads with a -70.2% price change compared with -87.9% for NKTX. Nkarta is the larger company by market cap ($161.2 million vs $151.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NERV | NKTX |
|---|---|---|
| Share price | $3.18 | $2.25 |
| Market cap | $151.84M | $161.16M |
| 1-day change | -1.24% | +1.35% |
| YTD return | -19.90% | +20.00% |
| 1-year return | +13.78% | +6.22% |
| 5-year return | -70.19% | -87.90% |
| EPS (TTM) | $-36.12 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.46 | $3.72 |
| 52-week low | $2.24 | $1.70 |
| Distance from 52-week high | -74.48% | -39.52% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +224.84% | +381.33% |
| Average volume | 183.63K | 613.16K |
| Shares outstanding | 47.75M | 71.62M |
| Employees | 7 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
NERV vs NKTX FAQ
Which is bigger, Minerva Neurosciences or Nkarta?
Nkarta (NKTX) is larger, with a market capitalization of $161.16M compared with $151.84M for Minerva Neurosciences (NERV).
Which stock has performed better over the past year, NERV or NKTX?
NERV returned +13.78% over the past 12 months, compared with +6.22% for NKTX (price return, excluding dividends). Past performance does not predict future results.
Are Minerva Neurosciences and Nkarta in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.